Recording: PARP inhibitors in prostate cancer. Part 1

Published Tue, 22 Feb 2022
Recorded WebinarProstate CancerOncologyEAU Section Of Oncological Urology
Organiser European School of Urology (ESU)
CME Not approved
Duration Approx. 60 minutes

Prof. Dr. D. Tilki (DE)

Prof. B. Tombal (BE)
Prof. Dr. H.G. Van Der Poel (NL)

PARP inhibitors in prostate cancer treatment is still a relatively new topic for most urologists. With this PARPi curriculum we offer urologists an educational programme addressing the following learning objectives:

1. Understanding the rationale for PARPi combinations as potential PCa treatments

2. Getting more insights on patient selection/identification for potential treatment with PARPi combinations

3. Learn the latest developments by discussing ongoing clinical trial design exploring PARPi combinations in Prostate Cancer

In a series of webinars we will tackle its role in prostate cancer treatment, discussing the latest evidence and a practical guide in how to use it in your daily practice.

Contact our organiser

European School of Urology (ESU)